As a long time investor in ACHN, I like your call. I do know there's a lot of pending news due out soon -- (1) ACH 3422 trial results in GT2 and GT3, (2) Sparta trials on 3422/3102 doublet 12/8/6 week treatment starting in June, (3) new tablet formulations for all 3 agents (3422, 3102, sovaprevir) for ease of use by patients, (4) competitor's drug regimens not faring so well for 6 week treatment, ... and many other items, which we will hear about in due course. It's all good!
What are your thoughts on something great for ACHN?
You did mention a possible GILD buyout. I see a buyout by any of the other Hep C players (MRK or ABBV or BMY or J&J) being equally likely.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM